Phaseline

Companies › Longevity Biotech Australia Pty Ltd (subsidiary)

Longevity Biotech Australia Pty Ltd (subsidiary): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LBT-3627
Synthetic peptide
–Phase 1Parkinson DiseaseFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06466525LBT-3627Phase 1Parkinson DiseaseNeurologyFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.